As the landscape of the K-beauty industry is rapidly being reshaped, VAIM, a medical aesthetics company that has risen sharply on the back of its skin booster product Juvelook, is emerging as one of the hottest merger and acquisition (M&A) targets this year.
With private equity firm Premier Partners launching a process to sell its controlling stake, some market observers estimate the company’s valuation could reach as high as 2 trillion won. Yet others offer a colder assessment, noting that being a good company and being a sellable company are not always the same.
VAIM headquarters view. / VAIM
According to industry sources, Premier Partners recently sent requests for proposals (RFPs) to major domestic and global investment banks (IBs) to appoint a lead adviser for the sale. While VAIM remains relatively under the radar among the general public, its corporate value is now believed to hover around 2 trillion won.
At the heart of that multibillion-dollar valuation is the company’s striking financial performance. According to its latest audit report, VAIM posted 66.4 billion won in revenue in 2024, more than tripling from a year earlier, while operating profit surged more than fivefold to 52.9 billion won.
Most strikingly, its operating margin reached 79.6%—a level rarely seen in manufacturing. That profitability has helped position VAIM not merely as a fast-growing company, but as one that has proven substantial cash-generation capability, drawing strong investor interest.
That growth has been driven overwhelmingly by a single product: Juvelook. The skin booster, designed to stimulate skin regeneration, has rapidly captured global demand as consumer preferences shift away from traditional fillers toward more natural-looking improvements. Shipment volume surpassed 1 million vials in 2024 and exceeded 2 million just a year later, underscoring explosive momentum. Industry watchers say the product has benefited not just from strong execution, but from a broader paradigm shift in the aesthetics market.
Technological differentiation has also been central to VAIM’s competitiveness. While traditional skin booster materials based on PLLA have faced concerns over nodule formation, VAIM addressed the issue through a PDLLA-based structure. By randomizing particle structures to allow more natural tissue integration, the company says it has improved both safety and efficacy. That innovation has reduced procedural burden for physicians, enhanced patient satisfaction, and accelerated market adoption.
VAIM has further expanded the franchise by segmenting its lineup into Juvelook, Juvelook Volume, Juvelook i and Juvelook G, covering indications from fine wrinkles to facial contouring. Analysts cite this as a textbook case of “focus with expansion”—leveraging a single core platform while serving diverse treatment needs.
Backed by such momentum, the company is also expanding aggressively overseas. VAIM has signed contracts in more than 80 countries and is selling products in 60 markets. Production capacity has nearly tripled with the launch of its second and third plants in Daejeon. That transformation from domestic success story to global player has made it an attractive target for both strategic investors (SIs) and international private equity firms.
That growth story has ultimately led to the sale process. Premier Partners recently began formal procedures by distributing RFPs to major investment banks, aiming to complete a transaction within the year. Given strong overseas interest, some market participants say a global investment bank could be selected as lead adviser.
For Premier Partners, the deal could prove a jackpot exit. The firm acquired VAIM in 2023 for roughly 70 billion to 80 billion won and subsequently increased its ownership stake to around 80% to 90%. With the company now potentially valued at more than 1 trillion won—and possibly up to 2 trillion—the investment’s internal rate of return (IRR) could surge dramatically within just two to three years.
Still, the market is far from universally optimistic. The biggest question is price. A valuation near 2 trillion won is widely seen as aggressive, even considering VAIM’s growth trajectory. With the M&A market recently cooling, the pool of buyers capable of underwriting multitrillion-won deals is limited.
Another uncertainty lies in the industry structure itself. While the skin booster market is growing rapidly, some argue barriers to entry are not insurmountably high. Rivals including GC Wellbeing, CGBIO and HLB Life Science are preparing next-generation products and intensifying competition. As fast as the market is expanding, competitive pressures could escalate just as quickly.
Investors are also watching VAIM’s concentration risk. Much of its revenue is tied to Juvelook, creating what some see as a single-product dependency. While that strategy has fueled rapid growth, a shorter-than-expected product life cycle could introduce earnings volatility—a factor that could weigh on valuation during negotiations.
Many in the market say the success of the sale may hinge on how convincingly VAIM can tell a “post-Juvelook” story. To attract large-scale global capital, investors may need confidence not just in current earnings, but in a sustainable growth strategy over the next five to 10 years.
Observers point to precedents. Aesthetic medical device maker Classys also pursued a sale backed by strong growth and profitability, only to face delays as lofty pricing expectations complicated negotiations. For many, it illustrated a harsh M&A reality: intrinsic value and transaction execution are not always aligned.
Even so, VAIM’s symbolic significance is difficult to ignore. The company reflects how K-beauty is expanding beyond cosmetics into high-value medical devices, while also showing Korean technology gaining recognition globally. In that sense, this transaction could mark an important milestone for the broader industry.
One industry official said, “VAIM is a rare case that combines financial performance, technological competitiveness and global scalability. But if current valuation expectations exceed what the market can absorb, the strategy could shift toward a partial stake sale or a phased exit instead.”
댓글
0